Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Acquisition of landmark building project
Represented a major German asset management company on the acquisition of a new landmark office building project in Central Stockholm. Due to the more
Intellectual property litigation and counseling services for a major world chemical producer
Represent a Fortune 500 company and major world producer of chemicals, fibers and plastics, by providing a full range of intellectual more
Trademark portfolio management for leading manufacturer of waterproof, breathable fabric
Represents leading manufacturer of waterproof, breathable fabric in connection with the enforcement of the company's trademarks. more
United States and international patent prosecution and counseling for Vanderbilt University
Represents Vanderbilt University in U.S. and international (China, Australia and European Patent Office) patent prosecutions in the area of methods more